Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy

NCT03471481 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2021-03-01

No results posted yet for this study

Summary

The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications.

Conditions

  • Epilepsy
  • Magnesium Deficiency
  • Vitamin D Deficiency

Interventions

OTHER

No Intervention. Study is Cross Sectional in nature

No Intervention. Study is cross sectional in nature

Sponsors & Collaborators

  • Drexel University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-10
Primary Completion
2019-08-01
Completion
2019-08-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03471481 on ClinicalTrials.gov